Atrioventricular Septal Defect (AVSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Atrioventricular septal defects (AVSD) are congenital heart conditions marked by varying degrees of atrial and ventricular septal defects and a shared or partially separated atrioventricular orifice. A partial AVSD involves specific features like an atrial septal defect, separate atrioventricular valves with a common junction, a ventricular septal defect, and a cleft mitral valve. On the other hand, a complete AVSD features a common atrioventricular valve with an atrial septal defect and an unrestricted inlet-type ventricular septal defect. The clinical presentation of AVSD depends on the type of defect, the size of the intracardiac shunt, and any accompanying heart malformations. Complete AVSD patients often show signs of pulmonary congestion and right heart failure early in life due to a substantial left-to-right shunt, significantly as pulmonary vascular resistance decreases after birth. Heart failure and Eisenmenger syndrome might develop earlier in cases with atrioventricular valve regurgitation, ventricular imbalance, or aortic coarctation. Patients with partial AVSD, without complex congenital heart issues and minimal valve regurgitation, usually remain asymptomatic in early childhood and are typically diagnosed incidentally based on findings like heart murmurs and fixed splitting due to an atrial septal defect. The prognosis for untreated AVSD is bleak, with roughly 50% of patients not surviving infancy due to heart failure or pulmonary infections. Those who survive beyond the first year often develop irreversible pulmonary vascular disease and eventually, experience a reversal of the shunt. Patients who undergo surgical repair have a 90% survival rate for around 15 years, although approximately 9% to 10% of them may require reoperation within that period. Most complications related to AVSD are linked to intracardiac shunting and atrioventricular valve regurgitation. Complete AVSD leads to right-sided heart overload, heart failure, and pulmonary congestion at a young age, contributing to a significant infant mortality rate. This shunt can lead to irreversible pulmonary vascular disease, pulmonary hypertension, and Eisenmenger syndrome without correction.

·       Approximately 2,118 babies (1 in 1,859 babies) are born with AVSD annually in the United States.

 

Thelansis’s “Atrioventricular Septal Defect (AVSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrioventricular Septal Defect (AVSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Atrioventricular Septal Defect (AVSD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atrioventricular Septal Defect (AVSD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Atrioventricular Septal Defect (AVSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Atrioventricular Septal Defect (AVSD), Atrioventricular Septal Defect (AVSD) market outlook, Atrioventricular Septal Defect (AVSD) competitive landscape, Atrioventricular Septal Defect (AVSD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more